ICH tackles inconsistent approaches towards evaluation of genotoxic impurities in drugs
This article was originally published in SRA
Executive Summary
The International Conference on Harmonisation has issued guidance explaining how companies can address genotoxic impurities in pharmaceuticals to limit the potential carcinogenic risk of their products1,2.